According to GuruFocus’ Insider Data, these are the largest CEO buys during the past week. The overall trend of purchases is illustrated in the chart below:
American Assets Trust CEO bought 65,577 shares
American Assets Trust Inc. (AAT, Financial) Chairman, CEO, President and 10% owner Ernest S. Rady bought 65,577 shares for $43.71 per share in the past week.
Rady bought 10,407 shares for $43.92 per share on Feb. 24; 35,200 shares for $44 per share on Feb. 28; and 19,970 shares for $43.1 per share on March 2. The stock price has decreased by 0.26% since.
American Assets is a full service, vertically integrated and self-administered real estate investment trust. It owns, operates, acquires and develops retail, office, multifamily and mixed-use properties. The company has a market cap of $2.77 billion. As of March 3 its shares traded at $42.99 with a price-earnings (P/E) ratio of 59.79.
Net income attributable to common stockholders was $8.9 million for the three months ended Dec. 31, 2016, compared to $8.2 million for the three months ended Dec. 31, 2015.
Plains GP Holdings CEO bought 50,000 shares
Plains GP Holdings LP (PAGP, Financial) Chairman of the Board and CEO Greg L. Armstrong bought 50,000 shares for $31.00 per share on March 1. The stock price has increased by 6.81% since.
Plains GP, through its general partner PAA GP Holdings LLC, is engaged in the transportation, storage, terminaling and marketing of crude oil, NGL and natural gas. The company has a market cap of $16.63 billion. As of March 3 its shares traded at $33.11 with a P/E ratio of 34.89.
Revenue for the three months ended Dec. 31, 2016 was $5.952 billion compared to $4.996 billion for the prior-year period.
OPKO Health CEO bought 98,400 shares
OPKO Health Inc. (OPK, Financial) CEO, Chairman and 10% owner Phillip Frost bought 98,400 shares for $7.56 per share in the past week.
Frost bought 3,600 shares for $8.45 per share on Feb. 24 and 94,800 shares for $7.53 per share on March 2. The stock price has decreased by 1.06% since.
OPKO is a biopharmaceutical and diagnostics company. It is engaged in the research and development of pharmaceutical products and vaccines. The company has a market cap of $4.15 billion. Its shares traded at $7.45 with a P/E ratio of -413.89 as of March 3.
Consolidated revenues for the three months ended December 31, 2016 of $275.5 million were consistent with the comparable period of 2015 revenue of $276.2 million. Net loss for the three months ended December 31, 2016 was $13.7 million compared with net income of $1.6 million for the 2015 period.
Executive VP-Administration Steven D. Rubin bought 2,000 shares of OPK stock on February 28, 2017 at a price of $8.11. The stock price has decreased by 8.14% since.
Biogen CEO bought 1,333 shares
Biogen Inc. (BIIB, Financial) CEO Michel Vounatsos bought 1,333 shares for $285.39 per share on Feb. 27. The stock price has increased by 4.37% since.
Biogen is a biopharmaceutical company. It discovers, develops, manufactures and markets therapies for neurological, autoimmune and hematologic disorders. The company has a market cap of $64.32 billion. As of March 3 its shares traded at $297.85 with a P/E ratio of 17.59.
Revenue for the fourth quarter of 2016 was $2.872 billion compared to $2.839 billion for the prior-year period. Net income for the quarter was $649 million compared to $832 million for the fourth quarter of 2015.
Executive Vice President and Chief Medical Officer Neuro and Neurodegenerat Alfred Sandrock sold 973 shares for $290.07 per share on March 1. The stock price has increased by 2.68% since.
AptarGroup CEO bought 2,000 shares
AptarGroup Inc. (ATR, Financial) President and CEO Stephan B. Tanda bought 2,000 shares for $75.21 per share on March 1. The stock price has increased by 1.1% since.
AptarGroup is a solution provider of packaging delivery solutions for the beauty, personal care, home care, prescription drug, consumer health care, injectables, food and beverage markets. The company has a market cap of $4.77 billion. As of March 3 its shares traded at $76.04 with a P/E ratio of 23.99.
For the quarter ended Dec. 31, 2016, reported sales decreased 1% to $539 million from $547 million a year ago.
Special Advisor to CEO Stephen J. Hagge sold 2,923 shares for $76.11 per share on March 1. The stock price has decreased by 0.09% since.
Director Peter Pfeiffer sold 143,000 shares for $73.2 per share on Feb. 15. The stock price has increased by 3.88% since.
Director King W. Harris sold 13,400 shares for $74.51 per share on Feb. 13. The stock price has increased by 2.05% since.
For the complete list of stocks that bought by their company CEOs, go to: CEO Buys.
Disclosure: I do not own stock in any of the companies mentioned in the article.
Start a free seven-day trial of Premium Membership to GuruFocus.
